Cargando…
Donepezil Beyond Alzheimer's Disease? A Narrative Review of Therapeutic Potentials of Donepezil in Different Diseases
Donepezil hydrochloride is an acetylcholine esterase inhibitor studied and approved to treat Alzheimer's disease (AD). However, this drug can have positive therapeutic potential in treating different conditions, including various neurodegenerative disorders such as other types of dementia, mult...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Brieflands
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10024338/ https://www.ncbi.nlm.nih.gov/pubmed/36942075 http://dx.doi.org/10.5812/ijpr-128408 |
_version_ | 1784909081417351168 |
---|---|
author | Pooladgar, Parham Sakhabakhsh, Mehdi Taghva, Arsia Soleiman-Meigooni, Saeed |
author_facet | Pooladgar, Parham Sakhabakhsh, Mehdi Taghva, Arsia Soleiman-Meigooni, Saeed |
author_sort | Pooladgar, Parham |
collection | PubMed |
description | Donepezil hydrochloride is an acetylcholine esterase inhibitor studied and approved to treat Alzheimer's disease (AD). However, this drug can have positive therapeutic potential in treating different conditions, including various neurodegenerative disorders such as other types of dementia, multiple sclerosis, Parkinson's disease, psychiatric and mood disorders, and even infectious diseases. Hence, this study reviewed the therapeutic potential of this drug in treating Alzheimer's and other diseases by reviewing the articles from databases including Web of Science, Scopus, PubMed, Cochrane, and Science Direct. It was shown that donepezil could affect the pathophysiology of these diseases via mechanisms such as increasing the concentration of acetylcholine, modulating local and systemic inflammatory processes, affecting acetylcholine receptors like nicotinic and muscarinic receptors, and activating various cellular signaling via receptors like sigma-1 receptors. Despite many therapeutic potentials, this drug has not yet been approved for treating non-Alzheimer's diseases, and more comprehensive studies are needed. |
format | Online Article Text |
id | pubmed-10024338 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Brieflands |
record_format | MEDLINE/PubMed |
spelling | pubmed-100243382023-03-19 Donepezil Beyond Alzheimer's Disease? A Narrative Review of Therapeutic Potentials of Donepezil in Different Diseases Pooladgar, Parham Sakhabakhsh, Mehdi Taghva, Arsia Soleiman-Meigooni, Saeed Iran J Pharm Res Review Article Donepezil hydrochloride is an acetylcholine esterase inhibitor studied and approved to treat Alzheimer's disease (AD). However, this drug can have positive therapeutic potential in treating different conditions, including various neurodegenerative disorders such as other types of dementia, multiple sclerosis, Parkinson's disease, psychiatric and mood disorders, and even infectious diseases. Hence, this study reviewed the therapeutic potential of this drug in treating Alzheimer's and other diseases by reviewing the articles from databases including Web of Science, Scopus, PubMed, Cochrane, and Science Direct. It was shown that donepezil could affect the pathophysiology of these diseases via mechanisms such as increasing the concentration of acetylcholine, modulating local and systemic inflammatory processes, affecting acetylcholine receptors like nicotinic and muscarinic receptors, and activating various cellular signaling via receptors like sigma-1 receptors. Despite many therapeutic potentials, this drug has not yet been approved for treating non-Alzheimer's diseases, and more comprehensive studies are needed. Brieflands 2022-08-16 /pmc/articles/PMC10024338/ /pubmed/36942075 http://dx.doi.org/10.5812/ijpr-128408 Text en Copyright © 2022, Author(s) https://creativecommons.org/licenses/by-nc/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited. |
spellingShingle | Review Article Pooladgar, Parham Sakhabakhsh, Mehdi Taghva, Arsia Soleiman-Meigooni, Saeed Donepezil Beyond Alzheimer's Disease? A Narrative Review of Therapeutic Potentials of Donepezil in Different Diseases |
title | Donepezil Beyond Alzheimer's Disease? A Narrative Review of Therapeutic Potentials of Donepezil in Different Diseases |
title_full | Donepezil Beyond Alzheimer's Disease? A Narrative Review of Therapeutic Potentials of Donepezil in Different Diseases |
title_fullStr | Donepezil Beyond Alzheimer's Disease? A Narrative Review of Therapeutic Potentials of Donepezil in Different Diseases |
title_full_unstemmed | Donepezil Beyond Alzheimer's Disease? A Narrative Review of Therapeutic Potentials of Donepezil in Different Diseases |
title_short | Donepezil Beyond Alzheimer's Disease? A Narrative Review of Therapeutic Potentials of Donepezil in Different Diseases |
title_sort | donepezil beyond alzheimer's disease? a narrative review of therapeutic potentials of donepezil in different diseases |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10024338/ https://www.ncbi.nlm.nih.gov/pubmed/36942075 http://dx.doi.org/10.5812/ijpr-128408 |
work_keys_str_mv | AT pooladgarparham donepezilbeyondalzheimersdiseaseanarrativereviewoftherapeuticpotentialsofdonepezilindifferentdiseases AT sakhabakhshmehdi donepezilbeyondalzheimersdiseaseanarrativereviewoftherapeuticpotentialsofdonepezilindifferentdiseases AT taghvaarsia donepezilbeyondalzheimersdiseaseanarrativereviewoftherapeuticpotentialsofdonepezilindifferentdiseases AT soleimanmeigoonisaeed donepezilbeyondalzheimersdiseaseanarrativereviewoftherapeuticpotentialsofdonepezilindifferentdiseases |